22nd Century Group to Participate in the HC Wainwright Conference on September 15, 2026

Rhea-AI Summary

22nd Century Group (Nasdaq: XXII) announced it will participate in the HC Wainwright Conference on September 15, 2026 at the Lotte New York Palace Hotel in New York. Chairman and CEO Larry Firestone and CFO Dan Otto are scheduled to attend, and investors can register and request meetings through their HC Wainwright representative.

The company highlighted its proprietary non-GMO reduced-nicotine tobacco plants, which contain about 95% less nicotine than traditional tobacco plants, and its VLN and Pinnacle VLN cigarettes. According to 22nd Century Group, VLN cigarettes are the only low-nicotine combustible cigarettes authorized by the FDA in the United States.

Market Context

The active S-3 resale registration covers 3,019,586 shares and states the company will not receive p...

Analysis

The active S-3 resale registration covers 3,019,586 shares and states the company will not receive proceeds from secondary sales. The filing context adds a capital-structure risk; short positioning was categorized as low, and no recent insider activity was reported.

Key Figures

Conference date: September 15, 2026 Company history: 28 years Nicotine reduction: 95% less nicotine

3 metrics

Conference date September 15, 2026 HC Wainwright Conference

Company history 28 years Company statement regarding its tobacco-harm-reduction activities

Nicotine reduction 95% less nicotine VLN cigarettes compared with traditional cigarettes

Historical Context

5 past events · Latest: Aug 13 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 13	Earnings report	Negative	-4.6%	Second-quarter revenue declined while operating and adjusted EBITDA losses widened.
Aug 04	Earnings date	Neutral	+5.0%	Company scheduled second-quarter results and a webcast for August 13.
Jul 16	Leadership change	Positive	-1.1%	Company appointed Katherine Rouse-Bailey as vice president of marketing.
May 21	Product launch	Positive	-1.8%	Pinnacle VLN trial launched in approximately 60 California stores.
May 18	Product launch	Positive	+6.6%	Pinnacle Pure launch targeted multiple national retailers and over 2,000 locations.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

XXII historically showed mixed reactions to company announcements, with positive operational news producing both declines and gains.

Key Terms

alkaloid biosynthesis

1 terms

alkaloid biosynthesis technical

"technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant"

Alkaloid biosynthesis is the set of natural chemical steps inside plants, fungi or microbes that build alkaloids — a class of nitrogen-containing molecules that include many medicines, stimulants and defensive toxins. For investors, controlling or scaling these pathways is like improving a factory assembly line: it affects how much of a valuable compound can be produced, the cost and consistency of supply, intellectual property and regulatory or safety risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MOCKSVILLE, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 28 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced that it will participate in the HC Wainwright Conference on September 15, 2026 at the Lotte New York Palace Hotel. Investors can register and request meetings with management via their HC Wainwright representative.

Attending the conference will be Larry Firestone, chairman and chief executive officer, and Dan Otto, chief financial officer.

The Company has posted an updated investor presentation online at https://ir.xxiicentury.com/.

About 22^nd Century Group, Inc.

22nd Century Group is pioneering the tobacco harm reduction movement by enabling smokers to take control of their nicotine consumption.

Our Technology is Tobacco

Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine compared to traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

Our Products

We created our flagship low nicotine cigarette products, the VLN^® cigarette and Pinnacle VLN^® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. Our VLN^® cigarettes are the lowest nicotine cigarettes in America^™ and have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

FDA Authorized

Our VLN^® cigarettes are the only low nicotine combustible cigarette authorized by the FDA in the United States.

VLN^® is a registered trademark of 22nd Century Limited LLC.

Learn more about 22^nd Century at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

Learn more about VLN^® cigarettes at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, and (iii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026 and Quarterly Reports on Form 10-Q filed on May 7, 2026 and August 14, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Daniel Otto
Chief Financial Officer & Investor Relations
22nd Century Group
investorrelations@xxiicentury.com

FAQ

When will 22nd Century Group (NASDAQ: XXII) present at the HC Wainwright Conference in 2026?

22nd Century Group is scheduled to participate on September 15, 2026. The event will be held at the Lotte New York Palace Hotel in New York. According to 22nd Century Group, investors can register and request meetings via their HC Wainwright representative.

Which 22nd Century Group (XXII) executives will attend the HC Wainwright Conference on September 15, 2026?

According to 22nd Century Group, chairman and chief executive officer Larry Firestone and chief financial officer Dan Otto will attend. Investors can request meetings with management through their HC Wainwright representative in connection with the conference.

How can investors access 22nd Century Group's latest investor presentation for NASDAQ: XXII?

22nd Century Group has posted an updated investor presentation on its investor relations website at https://ir.xxiicentury.com/. According to 22nd Century Group, investors can review this material ahead of or after the HC Wainwright Conference participation.

What are 22nd Century Group's VLN cigarettes and how much nicotine do they contain?

VLN cigarettes are 22nd Century Group's flagship low-nicotine combustible cigarette products. According to 22nd Century Group, they contain about 95% less nicotine than traditional cigarettes, using proprietary reduced-nicotine tobacco designed to help smokers control nicotine consumption.

Are 22nd Century Group's VLN cigarettes FDA authorized in the United States?

According to 22nd Century Group, VLN cigarettes are the only low-nicotine combustible cigarettes authorized by the FDA in the United States. The company positions this authorization as supporting its focus on tobacco harm reduction for adult smokers.

What technology underpins 22nd Century Group (XXII) reduced-nicotine tobacco products?

22nd Century Group uses patented technologies that regulate alkaloid biosynthesis in tobacco plants. According to 22nd Century Group, this results in non-GMO tobacco containing about 95% less nicotine than traditional plants, enabling commercial-scale production of its VLN and Pinnacle VLN products.